Contineum Therapeutics (CTNM) Stock Forecast & Price Target

$14.71 -0.65 (-4.23%)

(As of 02:30 PM ET)

Contineum Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 5 Analyst Ratings

Sell
0

Hold
0

Buy
5

Based on 5 Wall Street analysts who have issued ratings for Contineum Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 4 have given a buy rating, and 1 has given a strong buy rating for CTNM.

Consensus Price Target

$29.25
98.84% Upside

According to the 5 analysts' twelve-month price targets for Contineum Therapeutics, the average price target is $29.25. The highest price target for CTNM is $32.00, while the lowest price target for CTNM is $25.00. The average price target represents a forecasted upside of 98.84% from the current price of $14.71.

Get the Latest News and Ratings for CTNM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Contineum Therapeutics and its competitors.

CTNM Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	4 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$29.25	$29.50	$28.67	N/A
Forecasted Upside	98.84% Upside	76.75% Upside	55.12% Upside	N/A
Consensus Rating	Buy	Buy	Buy	N/A

"This Could Be Worse Than the Great Depression, the Dot-Com Crash, and the 2008 Crisis Combined" (Ad)

What Are These Billionaire Investors Afraid Of? Billionaires Warren Buffett, Stanley Druckenmiller, George Soros, and David Tepper have all sold off massive U.S. stock positions, including shares of Nvidia, Apple, and Bank of America. Billionaire Ray Dalio, who runs one of the world’s most successful hedge funds, says, “Things are going to get worse for our economy.” What are these billionaires so worried about?

Click here to see why experts and insiders may be preparing for the biggest financial crisis of the

CTNM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CTNM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Contineum Therapeutics Stock vs. The Competition

Type	Contineum Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.20	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	90.43% Upside	17,640.62% Upside	6.38% Upside
News Sentiment Rating	Neutral News See Recent CTNM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$32.00 ➝ $31.00	+74.45%
10/22/2024	Baird R W 0 of 5 stars	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/22/2024	Robert W. Baird 2 of 5 stars		Initiated Coverage	Outperform	$32.00	+99.13%
4/30/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$25.00	+56.25%
4/30/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$29.00	+81.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:57 PM ET.

CTNM Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Contineum Therapeutics is $29.25, with a high forecast of $32.00 and a low forecast of $25.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Contineum Therapeutics in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTNM shares.
: According to analysts, Contineum Therapeutics's stock has a predicted upside of 98.84% based on their 12-month stock forecasts.
: Over the previous 90 days, Contineum Therapeutics's stock had 1 upgrade by analysts.
: Contineum Therapeutics has been rated by research analysts at Baird R W, Robert W. Baird, and Royal Bank of Canada in the past 90 days.
: Analysts like Contineum Therapeutics more than other "medical" companies. The consensus rating for Contineum Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CTNM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

"This Could Be Worse Than the Great Depression, the Dot-Com Crash, and the 2008 Crisis Combined" (Ad)

Click here to see why experts and insiders may be preparing for the biggest financial crisis of the

This page (NASDAQ:CTNM) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Stock Forecast & Price Target